EUVIMEDEUVIMED entdecken
ÄquivalenzstudieRandomisierte kontrollierte Studie

Cytisine Versus Varenicline for Smoking Cessation in a Primary Care Setting: A Randomized Non-inferiority Trial

Tin Oreskovic iD, Sanja Percac-Lima, Jeffrey M Ashburner, Hrvoje Tiljak, Janez Rifel, Zalika Klemenc Ketiš, Stjepan Oreskovic iD

Nicotine and Tobacco Research · 19.08.2023 · 25 (9) · 1547-1555

DOI: 10.1093/ntr/ntad065 ↗

Kurz gefasst

Äquivalenzstudie in der Zeitschrift Nicotine and Tobacco Research, online erschienen am 09.06.2023. Verfasst von Tin Oreskovic und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Population Health, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Alkaloids, Smoking Cessation. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Global Research Awards for Nicotine Dependence, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

A smoking-cessation program was implemented as a randomized non-inferiority trial in primary care practices in Croatia and Slovenia to investigate whether a standard 4-week treatment with cytisine was at least as effective and feasible as a standard 12-week treatment with varenicline in helping smokers quit. Aims and Methods Out of 982 surveyed smokers, 377 were recruited to the non-inferiority trial: 186 were randomly assigned to cytisine and 191 to varenicline treatment. The primary cessation outcome was 7-day abstinence after 24 weeks, while the primary feasibility outcome was defined by adherence to the treatment plan. We also compared the rates of adverse events between the two treatment groups.

Results

The cessation rate after 24 weeks was 32.46% (62/191) in the varenicline group and 23.12% (43/186) in the cytisine group (odds ratio [OR]: 0.63, 95% credible interval [CI]: 0.39 to 0.98). Of 191 participants assigned to varenicline treatment 59.16% (113) were adherent, while 70.43% (131 of 186) were adherent in the cytisine group (OR: 1.65, 95% CI: 1.07 to 2.56). Participants assigned to cytisine experienced fewer total (incidence rate ratio [IRR]: 0.59, 95% CI: 0.43 to 0.81) and fewer severe or more extreme adverse events (IRR: 0.72, 95% CI: 0.35 to 1.47).

Conclusions

This randomized non-inferiority trial (n = 377) found the standard 4-week cytisine treatment to be less effective than the standard 12-week varenicline treatment for smoking cessation. However, adherence to the treatment plan, ie, feasibility, was higher, and the rate of adverse events was lower among participants assigned to cytisine treatment.

Implications

The present study found the standard 12 weeks of varenicline treatment to be more effective than the standard 4 weeks of cytisine treatment for smoking cessation in a primary care setting in Croatia and Slovenia. Participants assigned to cytisine, however, had a higher adherence to the treatment plan and a lower rate of adverse events. Estimates from the present study may be especially suitable for generalizations to high-smoking prevalence populations in Europe. Given the much lower cost of cytisine treatment, its lower rate of adverse events, and higher feasibility (but its likely lower effectiveness with the standard dosage regimen), future analyses should assess the cost-effectiveness of the two treatments for health policy considerations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlkaloidsSmoking CessationHumansAzocinesBenzazepinesNicotineNicotinic AgonistsPrimary Health CareQuinolizinesTreatment OutcomeVareniclineQuinolizidine Alkaloids

Substanzen

AlkaloidsAzocinesBenzazepinesNicotineNicotinic AgonistsQuinolizinesVareniclinecytisineQuinolizidine Alkaloids

Autor:innen und Institutionen

  • Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Big Data Institute, University of Oxford, Oxford, UK.
  • Harvard Medical School, Harvard University, Boston, MA, USA.
  • Chelsea HealthCare Center, Massachusetts General Hospital, Boston, MA, USA.
  • Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Andrija Štampar School of Public Health, University of Zagreb School of Medicine, Zagreb, Croatia.

ORCID-Profile: Tin Oreskovic, Stjepan Oreskovic

Förderung

  • Global Research Awards for Nicotine Dependence
  • Pfizer

Zitieren

APA

Oreskovic, T., Percac-Lima, S., Ashburner, J. M., Tiljak, H., Rifel, J., Klemenc Ketiš, Z., & Oreskovic, S. (2023). Cytisine Versus Varenicline for Smoking Cessation in a Primary Care Setting: A Randomized Non-inferiority Trial. Nicotine and Tobacco Research, 25(9), 1547-1555. https://doi.org/10.1093/ntr/ntad065

Vancouver

Oreskovic T, Percac-Lima S, Ashburner JM, Tiljak H, Rifel J, Klemenc Ketiš Z, et al. Cytisine Versus Varenicline for Smoking Cessation in a Primary Care Setting: A Randomized Non-inferiority Trial. Nicotine and Tobacco Research. 2023;25(9):1547-1555. doi:10.1093/ntr/ntad065

BibTeX
@article{Oreskovic2023,
  author = {Oreskovic, Tin and Percac-Lima, Sanja and Ashburner, Jeffrey M and Tiljak, Hrvoje and Rifel, Janez and Klemenc Ketiš, Zalika and Oreskovic, Stjepan},
  title = {Cytisine Versus Varenicline for Smoking Cessation in a Primary Care Setting: A Randomized Non-inferiority Trial},
  journal = {Nicotine and Tobacco Research},
  year = {2023},
  volume = {25},
  number = {9},
  pages = {1547--1555},
  doi = {10.1093/ntr/ntad065}
}
Kostenlos starten →